Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XEN-101
- Development stage
- Discontinued
- Lead developer
- Xeno Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XEN-101 is an orally administered, gut-restricted small molecule being developed by Xeno Biosciences for the treatment of obesity and metabolic diseases. The drug is designed to mimic the physiological and metabolic benefits of Roux-en-Y Gastric Bypass (RYGB) surgery, which is considered a highly effective surgical intervention for weight loss. XEN-101 works by modulating the gut environment and microbiome to induce a metabolic state similar to that achieved post-surgery, potentially offering a non-invasive alternative to bariatric procedures. As of early 2024, XEN-101 is in Phase 1b clinical development to evaluate its safety, tolerability, and pharmacodynamic effects in individuals with obesity.
Beyond the preview
Go deeper on XEN-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XEN-101.